Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO). In a filing disclosed on April 07th, the Representative disclosed that they had bought between $1,001 and $15,000 in BridgeBio Pharma stock on March 3rd. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of MACOM Technology Solutions (NASDAQ:MTSI) on 3/27/2026.
• Purchased $1,001 – $15,000 in shares of StandardAero (NYSE:SARO) on 3/27/2026.
• Purchased $1,001 – $15,000 in shares of FirstService (NASDAQ:FSV) on 3/27/2026.
• Sold $1,001 – $15,000 in shares of Charles Schwab (NYSE:SCHW) on 3/27/2026.
• Sold $1,001 – $15,000 in shares of Advanced Energy Industries (NASDAQ:AEIS) on 3/27/2026.
• Sold $1,001 – $15,000 in shares of Flex (NASDAQ:FLEX) on 3/27/2026.
• Purchased $1,001 – $15,000 in shares of LPL Financial (NASDAQ:LPLA) on 3/27/2026.
• Purchased $1,001 – $15,000 in shares of DoorDash (NASDAQ:DASH) on 3/27/2026.
• Sold $1,001 – $15,000 in shares of Viavi Solutions (NASDAQ:VIAV) on 3/27/2026.
• Purchased $15,001 – $50,000 in shares of Fabrinet (NYSE:FN) on 3/27/2026.

BridgeBio Pharma Price Performance

BBIO stock traded up $1.18 during midday trading on Thursday, hitting $75.32. The company’s stock had a trading volume of 1,244,452 shares, compared to its average volume of 2,732,037. The company’s fifty day moving average price is $71.05 and its 200 day moving average price is $68.51. BridgeBio Pharma, Inc. has a twelve month low of $30.08 and a twelve month high of $84.94. The stock has a market capitalization of $14.60 billion, a P/E ratio of -19.93 and a beta of 1.09.

BridgeBio Pharma (NASDAQ:BBIO) last posted its quarterly earnings data on Tuesday, February 24th. The company reported ($1.00) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.25). The firm had revenue of $154.18 million for the quarter, compared to the consensus estimate of $150.71 million. BridgeBio Pharma’s revenue was up 2521.2% on a year-over-year basis. During the same period last year, the company posted ($1.40) EPS. Equities analysts expect that BridgeBio Pharma, Inc. will post -3.67 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently commented on BBIO shares. Truist Financial increased their price target on BridgeBio Pharma from $86.00 to $95.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. Mizuho increased their price objective on BridgeBio Pharma from $91.00 to $106.00 and gave the company an “outperform” rating in a report on Wednesday, March 18th. Barclays reissued an “overweight” rating on shares of BridgeBio Pharma in a research note on Tuesday, March 10th. Leerink Partners restated an “outperform” rating and set a $98.00 target price on shares of BridgeBio Pharma in a report on Thursday, March 12th. Finally, HC Wainwright upped their price target on shares of BridgeBio Pharma from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Tuesday, February 17th. Twenty-four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, BridgeBio Pharma currently has an average rating of “Moderate Buy” and a consensus price target of $87.38.

Insider Buying and Selling

In other BridgeBio Pharma news, Director Andrea Ellis sold 64,921 shares of the stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $64.87, for a total value of $4,211,425.27. Following the transaction, the director directly owned 18,589 shares of the company’s stock, valued at $1,205,868.43. This represents a 77.74% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Thomas Trimarchi sold 13,600 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $74.72, for a total transaction of $1,016,192.00. Following the sale, the chief financial officer owned 336,585 shares of the company’s stock, valued at $25,149,631.20. This trade represents a 3.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 197,084 shares of company stock valued at $13,649,619. 18.20% of the stock is currently owned by insiders.

Institutional Trading of BridgeBio Pharma

A number of hedge funds have recently made changes to their positions in BBIO. Brooklands Fund Management Ltd acquired a new position in shares of BridgeBio Pharma during the 4th quarter worth approximately $210,348,000. Price T Rowe Associates Inc. MD lifted its holdings in BridgeBio Pharma by 144.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,828,746 shares of the company’s stock valued at $292,862,000 after purchasing an additional 2,261,181 shares during the last quarter. Janus Henderson Group PLC boosted its position in BridgeBio Pharma by 25.8% during the fourth quarter. Janus Henderson Group PLC now owns 11,000,457 shares of the company’s stock worth $841,349,000 after purchasing an additional 2,259,378 shares during the period. Norges Bank bought a new position in BridgeBio Pharma during the fourth quarter worth $116,802,000. Finally, Wellington Management Group LLP increased its holdings in shares of BridgeBio Pharma by 130.4% in the fourth quarter. Wellington Management Group LLP now owns 2,348,731 shares of the company’s stock valued at $179,654,000 after purchasing an additional 1,329,537 shares during the last quarter. 99.85% of the stock is owned by institutional investors and hedge funds.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.